Security key
G2851K120
Drugs Made In America Acquisition II Corp. - UNIT 09/16/2030 (DMIIU)
CUSIP: G2851K120
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / UNIT 09/16/2030
- Total 13F shares
- 46,354,933
- Total 13F value
- $461,007,912
- Share change
- +45,997,831
- SEC-reported price per share
- $9.94
- Number of holders
- 76
- Value change
- +$457,456,533
- Number of buys
- 75
Report period
Q3 2025
Institutions
76
Top holders
10
DMIIU full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
Drugs Made In America Acquisition II Corp. SEC filings
Drugs Made In America Acquisition II Corp. company facts
Broader feeds
Reporting periods
Holder history for CUSIP G2851K120
Recent filing periods:
Ownership snapshot
Top reported holders of DMIIU - Drugs Made In America Acquisition II Corp. - UNIT 09/16/2030 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Drugs Made In America Acq...
Disclosed value leader
Catherine Do
Comparable rows
0/6
Latest evidence
26 Sep 2025
3/4/5
Highest disclosed value: $987,000
6 rows are not safely comparable across share classes.
Quick read
Catherine Do has the largest disclosed position value at $987K.
0 of 6 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Catherine Do's linked filing trail.
Disclosed position value
Top 2
Catherine Do
$987K
Myron W. Shulgan
$987K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 6 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Drugs Made In America Acquisition II LLC |
3/4/5
10%+ Owner
|
—
denominator unverified
|
—
6,708,333 shares
|
— | 26 Sep 2025 |
| Lynn Stockwell |
3/4/5
CEO and Exe. Chair of Board, Director, 10%+ Owner
|
—
denominator unverified
|
—
6,708,333 shares
|
— | 26 Sep 2025 |
| Catherine Do |
3/4/5
Director
|
—
denominator unverified
|
$987,000
100,000 shares
|
— | 26 Sep 2025 |
| Myron W. Shulgan |
3/4/5
Director
|
—
denominator unverified
|
$987,000
100,000 shares
|
— | 26 Sep 2025 |
| G. Sridhar Prasad |
3/4/5
Director
|
—
denominator unverified
|
—
100,000 shares
|
— | 26 Sep 2025 |
| Glenn C. Worman |
3/4/5
CFO
|
—
denominator unverified
|
—
100,000 shares
|
— | 26 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
76
Shares
46,354,933
Rows available
76
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q1 2026 Across Filers
Q1 2026 holders
14
Q3 2025 holders
76
Holder diff
62
| Investor | Q1 2026 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q1 2026 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend